Epigral Limited has disclosed its audited consolidated and standalone financial results for the fourth quarter and full year ended March 31, 2026, pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 2, 2026. Newspaper advertisements were published on May 3, 2026 and May 4, 2026 in the Financial Express (English and Gujarati editions) and Jai Hind (Gujarati edition).

Consolidated Financial Performance

Epigral's consolidated financial results reflect the company's performance across the fourth quarter and the full financial year ended March 31, 2026. The following table presents the key consolidated financial metrics (₹ In Crore, except as stated otherwise):

Standalone Financial Performance

The standalone financial results for the quarter and year ended March 31, 2026 are summarised below (₹ In Crore, except as stated otherwise):

Regulatory Compliance and Publication Details

The financial results have been prepared in compliance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs. The results represent an extract of the detailed format filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial results is available on the websites of the stock exchanges as well as on the company's website at www.epigral.com . The results were signed by Maulin Patel, Chairman and Managing Director (DIN 02006947), on behalf of the Board of Directors, from Ahmedabad, dated May 2, 2026.

Epigral Limited has informed the stock exchanges of the availability of the audio recording from its conference call discussing Q4 FY2026 financial results. The conference call was held on Saturday, 2 May 2026 at 4:30 p.m., and the disclosure was filed with the exchanges on 3 May 2026.

Regulatory Compliance Disclosure

The communication was made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule-III Part-A thereof. Epigral has submitted the filing to both the National Stock Exchange of India Limited and BSE Limited, requesting the exchanges to record the information and disseminate it to their members.

Audio Recording Availability

The audio recording of the Q4 FY2026 results conference call has been made publicly accessible through the company's official website. The key details of the disclosure are summarised below:

The filing was signed by Gaurang Trivedi, Company Secretary & Compliance Officer (M. No. A22307), on behalf of Epigral Limited, headquartered at Epigral Tower, Behind Safal Profitaire, Corporate Road, Prahladnagar, Ahmedabad 380015, Gujarat, India.